Vaccination Mission

The last day of 2020 marked a milestone in the research and development of inactivated vaccines to fight COVID-19 in China. At a December 31 press conference organized by the State Council Joint Prevention and Control Mechanism Against COVID-19, the National Medical Products Administration announced that it granted conditional emergency usage authorization for an inactivated vaccine for COVID-19 developed by Beijing Institute of Biological Products Co., Ltd. (BJIBP), a subsidiary of China National Biotec Group (CNBG) under China National Pharmaceutical Group (Sinopharm). It was the first COVID-19 vaccine authorized for emergency use in China.

1 27 28 29